Sign in
Not yet recruitingPhase 2

Ecnoglutide tablets for overweight or obesity in Chinese adults

Tests ecnoglutide tablets against placebo in Chinese adults with overweight or obesity.

Key facts

Who runs it
Hangzhou Sciwind Biosciences Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Status
Not yet recruiting
Phase
Phase 2
People taking part
180 people, planned
Started
10 Nov 2026
Expected to end
28 Jan 2028
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ecnoglutide tablet
  • placebo with matching dosage
Record updated
10 November 2026

Who can take part

The trial is looking for adults aged 18 to 65 with overweight or obesity, with or without a weight-related health problem, who have not had a big recent change in body weight.

Age
18 Years to 65 Years
Sex
All sexes can join.
Disease stage
BMI of 28.0 kg/m^2 or more, with or without other health problems. Or BMI from 24.0 kg/m^2 up to less than 28.0 kg/m^2 with at least one health problem such as prediabetes, high blood pressure, abnormal blood fats, fatty liver, sleep apnea or weight-bearing joint pain.
Earlier treatment
No major stomach or bowel surgery and no weight-loss (metabolic) surgery in the past; gallbladder or appendix removal is allowed. No major surgery planned during the study.
Biomarker or test result
Body weight changed by less than 5% in the 3 months before consent (self-reported). HbA1c below 6.5% (48 mmol/mol), fasting blood glucose below 7.0 mmol/L (126 mg/dL) and 2-hour OGTT blood glucose below 11.1 mmol/L (200 mg/dL) at screening.
Main reasons for not taking part
  • Overweight or obesity caused by a hormone disorder, such as Cushing's syndrome
  • Other significant hormone or thyroid disease, including medullary thyroid carcinoma or personal or family history of MEN2
  • Significant heart or brain blood vessel disease in the 6 months before screening
  • Significant stomach or bowel disease in the 6 months before screening
  • Blood sugar levels in the diabetes range at screening
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • At the time of informed consent, BMI≥28.0 kg/m\^2 regardless of comorbidities, or 24.0kg/m\^2≤BMI<28.0 kg/m\^2 with at least one of the comorbidities (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, weight-bearing joint pain, etc.)
  • Self-declaration of body weight change <5% within 3 months prior to informed consent

Who cannot take part

  • Diagnosis of cardiovascular or cerebrovascular diseases with clinical significance within 6 months prior to screening, including but not limited to myocardial infarction, coronary angioplasty or bypass surgery, valvular heart disease or valve repair, unstable angina, transient ischemic attack, acute stroke, acute coronary syndrome, congestive heart failure classified as New York Heart Association class III or IV, clinically significant arrhythmias requiring treatment, and cerebrovascular accidents, etc
  • Diagnosis of gastrointestinal diseases with clinical significance within 6 months prior to screening, including but not limited to inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, dyspepsia, clinical gastric emptying abnormalities (such as pyloric obstruction), etc
  • Diagnosis of overweight or obesity due to endocrine disorders , such as Cushing's syndrome
  • Diagnosis of other endocrine disorders with clinical significance, including but not limited to hyperthyroidism or hypothyroidism, thyroid nodules (imaging shows C-TIRADS≥ class 4A), Medullary thyroid carcinoma, or personal or family history of type 2 multiple endocrine tumor syndrome (MEN2), etc
  • History of major gastrointestinal surgery (except cholecystectomy or appendectomy), or metabolic surgery, or plan to undergo major surgery during the study period
  • HbA1c ≥6.5% or fasting blood glucose ≥7.0 mmol/L, or OGTT 2-hour blood glucose ≥11.1 mmol/L, at screening
  • Clinical laboratory test results with clinical significance

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Weight management

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of the study is to evaluate the safety and efficacy of oral ecnoglutide tablets in Chinese participants with overweight or obesity

The 5 groups in the trial

  • oral ecnoglutide dose 1Treatment being tested

    once daily from week1 to week 8, then once weekly from week 9 to week 24

    Treatment: ecnoglutide tablet

  • oral ecnoglutide dose 2Treatment being tested

    once daily from week1 to week 8, then once weekly from week 9 to week 24

    Treatment: ecnoglutide tablet

  • oral ecnoglutide dose 3Treatment being tested

    once daily from week1 to week 12, then once weekly from week 13 to week 24

    Treatment: ecnoglutide tablet

  • PlaceboPlacebo, for comparison

    once daily from week1 to week 8 or week 12, then once weekly from week 9 or week 13 to week 24

    Treatment: placebo with matching dosage

  • oral ecnoglutide dose 4Treatment being tested

    once daily from week1 to week 12, then once weekly from week 13 to week 24

    Treatment: ecnoglutide tablet

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Safety and Efficacy of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Plain-language title
Ecnoglutide tablets for overweight or obesity in Chinese adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07929298, who can take part
Record updated
10 November 2026